Sanam Loghavi

Medical Genetics

1515 Holcombe Blvd
Houston, TX 77030

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 374 publications

Erratum: Risk Prognostication After Hypomethylating Agents Combined With Venetoclax in AML: The PRISM Risk Model.

Erratum: Risk Prognostication After Hypomethylating Agents Combined With Venetoclax in AML: The PRISM Risk Model.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: July 27, 2026

Erratum: All-Oral Combination of Revumenib, Decitabine, and Venetoclax for Relapsed or Refractory AML (SAVE).

Erratum: All-Oral Combination of Revumenib, Decitabine, and Venetoclax for Relapsed or Refractory AML (SAVE).

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: July 23, 2026

Molecular subtypes and genetic diagnostics in B-cell acute lymphoblastic leukemia.

Molecular subtypes and genetic diagnostics in B-cell acute lymphoblastic leukemia.

Journal: Human pathology

Published: July 13, 2026

Introduction to special issue on leukemia.

Introduction to special issue on leukemia.

Journal: Human pathology

Published: July 07, 2026

Risk Prognostication After Hypomethylating Agents Combined With Venetoclax in AML: The PRISM Risk Model.

Risk Prognostication After Hypomethylating Agents Combined With Venetoclax in AML: The PRISM Risk Model.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: July 02, 2026

All-Oral Combination of Revumenib, Decitabine, and Venetoclax for Relapsed or Refractory AML (SAVE).

All-Oral Combination of Revumenib, Decitabine, and Venetoclax for Relapsed or Refractory AML (SAVE).

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: June 11, 2026

Chronic Myelomonocytic Leukemia Revisited: A Comprehensive Review with Emphasis on the Oligomonocytic Subtype.

Chronic Myelomonocytic Leukemia Revisited: A Comprehensive Review with Emphasis on the Oligomonocytic Subtype.

Journal: Human pathology

Published: June 03, 2026

p53 Immunohistochemistry Is a Reliable Method for Assessing TP53 Allelic and Functional Status in TP53-Mutated Cases.

p53 Immunohistochemistry Is a Reliable Method for Assessing TP53 Allelic and Functional Status in TP53-Mutated Cases.

Journal: American journal of hematology

Published: May 14, 2026

Next-generation IHC: identifying TP53 mutation origin in a bone marrow with concurrent CLL and AML.

Next-generation IHC: identifying TP53 mutation origin in a bone marrow with concurrent CLL and AML.

Journal: Blood

Published: May 14, 2026

Chronic Myelomonocytic Leukemia: History, Pathobiology, Diagnostic Controversies, and Evolving Classification.

Chronic Myelomonocytic Leukemia: History, Pathobiology, Diagnostic Controversies, and Evolving Classification.

Journal: Current hematologic malignancy reports

Published: May 13, 2026

Molecular Pathology of Myeloid Neoplasms.

Molecular Pathology of Myeloid Neoplasms.

Journal: Surgical pathology clinics

Published: May 06, 2026

RAS Pathway Activation and Microenvironmental Adaptation as Hallmarks of Myeloid Sarcoma.

RAS Pathway Activation and Microenvironmental Adaptation as Hallmarks of Myeloid Sarcoma.

Journal: Blood cancer discovery

Published: May 01, 2026

Showing 1-12 of 374

Last Updated: 09/26/2026